Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(15):1205-1207; doi:10.1093/jnci/92.15.1205
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fintor, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fintor, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 15, 1205-1207, August 2, 2000
© 2000 Oxford University Press

NEWS

Melanoma Vaccine Momentum Spurs Interest, Investment

Lou Fintor

With one melanoma vaccine already approved for commercial use in Canada, another recently launched within a global vaccine trial network, and several more nearing the final phases of testing, corporate enterprises are teaming up with hospitals, universities, governments—even each other—in anticipation of potentially huge payoffs.

More than 95 different cancer vaccines are in development by more than 50 companies. Dozens are for melanoma alone, which can be one of the most deadly of all cancers and for which there are few efficacious treatments in advanced disease. With more than 47,000 cases, . . . [Full Text of this Article]

‘Prime-Boost’ Vaccine

Approval This Year?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?